Efficacy of 1-Year Cavacurmin Therapy in Reducing Prostate Growth in Men Suffering from Lower Urinary Tract Symptoms

We aim to assess the effect of Cavacurmin on prostate volume (PV), lower urinary tract symptoms (LUTS) and micturition parameters in men after 1 year of therapy. From September 2020 to October 2021, data from 20 men with LUTS/benign prostatic hyperplasia and PV ≥40 mL who were on therapy with α1-adrenoceptor antagonists plus Cavacurmin were retrospectively compared with 20 men on only α1-adrenoceptor antagonists. Patients were evaluated at baseline and after 1 year using the International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA), maximum urinary flow (Qmax) and PV. A Mann-Whitney U-test and Chi-square were used to assess the difference between the two groups. A comparison of paired data was performed with the Wilcoxon signed-rank test. Statistical significance was set at -value < 0.05. There was no statistically significant difference in baseline characteristics between the two groups. At the 1-year follow-up, PV [55.0 (15.0) vs. 62.5 (18.0) mL, = 0.04)], PSA [2.5 (1.5) ng/mL vs. 3.05 (2.7) vs. = 0.009] and IPSS [13.5 (3.75) vs. 18 (9.25) = 0.009] were significantly lower in the Cavacurmin group. Qmax was significantly higher in the Cavacurmin group [15.85 (2.9) vs. 14.5 (4.2), = 0.022]. PV was reduced to 2 (5.75) mL in the Cavacurmin group from baseline, while it increased to 12 (6.75) mL in the α1-adrenoceptor antagonists group ( < 0.001). PSA decreased in the Cavacurmin group [-0.45 (0.55) ng/mL], whereas it increased in the α1-adrenoceptor antagonists group [0.5 (0.30) ng/mL, < 0.001]. In conclusion, one-year Cavacurmin therapy was able to block prostate growth with a concomitant decrease in PSA value from baseline. The association of Cavacurmin with α1-adrenoceptor antagonists had a more beneficial effect compared to patients on α1-adrenoceptor antagonists alone but this needs further larger studies to be confirmed, particularly in the long-term.